Chimerix’s (CMRX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Chimerix (NASDAQ:CMRX) in a research report report published on Tuesday,RTT News reports. Wedbush currently has a $7.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $6.00. Wedbush also issued estimates for Chimerix’s Q4 2025 earnings at $0.74 EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.58 EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research note on Tuesday.

Chimerix Trading Up 1.8 %

Shares of NASDAQ:CMRX opened at $5.17 on Tuesday. The company has a market cap of $464.99 million, a PE ratio of -5.50 and a beta of 0.35. The company’s 50 day moving average is $3.72 and its two-hundred day moving average is $1.92. Chimerix has a 52 week low of $0.75 and a 52 week high of $5.53.

Insider Buying and Selling at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 20,760 shares of company stock worth $91,175 over the last three months. Insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

Hedge funds have recently made changes to their positions in the company. Bender Robert & Associates purchased a new stake in shares of Chimerix in the 4th quarter valued at about $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in Chimerix in the fourth quarter valued at approximately $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix in the 4th quarter valued at $62,000. Diadema Partners LP purchased a new position in shares of Chimerix during the fourth quarter worth about $101,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Chimerix in the 4th quarter valued at approximately $130,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.